Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06297941 · ClinicalTrials.gov registry record · Phase 1

Study of REM-422 in Patients With AML or Higher Risk MDS

A Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, sponsored by Remix Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
100
Enrollment target
9
Study locations

NCT06297941 is a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes that is actively recruiting participants, run by Remix Therapeutics. The registered enrollment target is 100 participants, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (14% lower). The trial reports 9 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06297941, a Phase 1 study of Acute Myeloid Leukemia and Myelodysplastic Syndromes, is actively recruiting participants, sponsored by Remix Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
100 participants
Enrollment target
9
Study locations

Study Summary

The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

Conditions Studied

Acute Myeloid Leukemia Myelodysplastic Syndromes Acute Myeloid Leukemia Refractory Higher-risk Myelodysplastic Syndromes

Interventions

  • DRUG REM-422

Study Locations (9)

Other

  • Centre Hospitalier Universitaire (CHU) de Bordeaux - Bordeaux
  • AP-HP - Hôpital Saint-Louis - Paris
  • IUCT-Oncopole - Toulouse
  • Institut de Cancerologie Gustave-Roussy - Villejuif

California

  • City of Hope - Duarte

Florida

  • Moffitt Cancer Center - Tampa

Massachusetts

  • Massachusetts General Hospital - Boston

New York

  • Memorial Sloan Kettering - New York

Texas

  • MD Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2024-04-26
Est. Completion 2027-06-15
Phase Phase 1

Sponsor

Remix Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06297941

The ClinicalTrials.gov registry entry for NCT06297941 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 116-participant average among 306 other Acute Myeloid Leukemia trials with a reported enrollment target (14% lower). The listed sponsor is Remix Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Acute Myeloid Leukemia appearing as the primary indexed condition, and to 1 intervention - of which REM-422 is the first listed.

NCT06297941 reports 9 study locations spanning 6 distinct geographic areas - top geographies include Other, California, Florida.

Frequently Asked Questions

What is clinical trial NCT06297941 about?

NCT06297941 is a clinical study titled "Study of REM-422 in Patients With AML or Higher Risk MDS". The goal of this study is to determine the safety and antitumor effects of REM-422, a MYB mRNA degrader, in people with Higher Risk MDS and relapsed/refractory AML

What is the current status of trial NCT06297941?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2024-04-26. Estimated completion is 2027-06-15.

What conditions does trial NCT06297941 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Acute Myeloid Leukemia Refractory, Higher-risk Myelodysplastic Syndromes.

What interventions are being tested in trial NCT06297941?

The interventions under investigation include: REM-422 (DRUG).

Who is sponsoring clinical trial NCT06297941?

This trial is sponsored by Remix Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06297941 being conducted?

This trial has 9 study locations across California, Florida, Massachusetts, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia

All registered trials for this condition

Myelodysplastic Syndromes

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.